Differentially expressed genes in adipocytokine signaling pathway of adipose tissue in pregnancy

Dotun Ogunyemi¹,²,*, Jun Xu³, Arnold M. Mahesan¹, Steve Rad¹, Eric Kim³, Jacqueline Yano¹, Carolyn Alexander¹, Jerome I. Rotter², and Y.-D. Ida Chen⁴

¹Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, USA
²Department of Medical Education, David Geffen School of Medicine at UCLA, Los Angeles, USA
³Department of Medical Genetics, Cedars-Sinai Medical Center, Los Angeles, USA
⁴Department of Endocrinology, Cedars-Sinai Medical Center, Los Angeles, USA

Abstract

Objective—To profile the differential gene expression of the KEGG Adipocytokine Signaling pathway in omental compared to subcutaneous tissue in normal pregnancy.

Study Design—Subjects included 14 nonobese, normal glucose tolerant, healthy pregnant women. Matched omental and subcutaneous tissue were obtained at elective cesarean delivery. Gene expression was evaluated using microarray and validated by RT-PCR. Differential gene expression was defined as ≥2.5 fold increase at p < 0.05.

Results—Six genes were significantly downregulated with two upregulated genes in omental tissue. Downregulation of Adiponectin and Insulin Receptor substrate, key genes mediating insulin sensitivity, were observed with borderline upregulation of GLUT-1. There were downregulations of CD36 and acyl-CoA Synthetase Long-chain Family Member 1 which are genes involved in fatty acid uptake and activation. There was a novel expression of Carnitine palmitoyltransferase 1C.

Conclusion—Differential gene expression of Adipocytokine Signaling Pathway in omental relative to subcutaneous adipose tissue in normal pregnancy suggests a pattern of insulin resistance, hyperlipidemia, and inflammation.

Keywords

Adipose Tissue; Pregnancy; Adipocytokine Pathway; Insulin Resistance

Copyright © 2013 Dotun Ogunyemi et al.
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Corresponding Author: dotunogunyemi@hotmail.com.
1. INTRODUCTION

Pregnancy is associated with changes in the regulation of glucose metabolism and the development of insulin resistance particularly during the second and third trimesters [1] of all pregnancies.

However, there is no consensus regarding the precise pathophysiology of insulin resistance, which is perceived as causative of gestational diabetes mellitus. It has also been suggested that the observed increase in body fat mass from the 1st trimester throughout pregnancy may be causally associated with decrease in insulin sensitivity [2].

Intra-abdominal (omental or visceral) adipose has been implicated as a major factor in pathophysiology of insulin resistance [3]. It has been observed that visceral fat accumulation increases during pregnancy [4]. Further, Martin et al have noted a significant association between visceral adipose tissue-depth above upper quartile value on ultrasound with positive glucose challenge test in later pregnancy, with no such associations seen for subcutaneous adipose tissue [5].

Adipose tissue is metabolically active, producing adipocytokines that exert effects in energy homeostasis and insulin resistance. The KEGG Adipocytokine Signaling Pathway (Figure 1) [6,7] describes signaling cascades arising from the adipocytokines that have been implicated in insulin resistance and sensitivity: TNF-alpha, leptin and adiponectin. Leptin is increased in pregnancies complicated by pre-eclampsia, BMI > 25, gestational diabetes, or hyperinsulinemia [8–11]. Adiponectin is an adipocytokine that has been demonstrated to have antiatherogenic, anti-inflammatory, and antidiabetic roles [12]. Adiponectin has been correlated with insulin sensitivity [13]. Decreased serum adiponectin is consistently seen in women with gestational diabetes independent of body mass index, strongly suggesting a role for adiponectin in modulating insulin resistance during gestation [14]. In late pregnancy, the placenta Produces and secretes adiponectin [15]. Adiponectin has also been observed to play a role in adapting energy metabolism at the maternal-fetal interface [15]. Metabolic changes associated with expanding adipose tissue are linked to subclinical inflammation which has been demonstrated to be mediated by cytokines such as TNF-alpha and IL-6 [16]. A signaling cascade arising from TNF-alpha is shown in the KEGG pathway (Figure 1), resulting in increased insulin resistance.

There is a paucity of studies examining differential gene expression of the adipocytokine signaling pathway. In the present investigation, we examine differential gene expression in omental and subcutaneous adipose depots in late-term gravid women as relevant to the adipocytokine signaling pathway. We performed this analysis to further elucidate the relative role of the various adipose depots in glucose homeostasis in normal pregnancy in non-obese women. We hypothesize that we will observe changes in differential gene expression in omental adipose consistent with a pattern of relative insulin resistance.

Identifying mechanisms of insulin resistance associated with various adipose tissue depots may help to better elucidate the pathogenesis of insulin resistance, which may have practical implications in the management of diabetes and its complications.
2. MATERIALS AND METHODS

2.1. Adipose Tissue Collection

This is a prospective study on investigating the pathophysiology of insulin resistance and diabetes in pregnancy. We recruited pregnant women between 18 to 45 years during prenatal care. Pregnant women were eligible for this study if they had a BMI < 30; were to be scheduled for an elective cesarean delivery and had a normal glucose challenge test performed during prenatal care. Informed consent was obtained, demographic information was obtained, and patients underwent routine prenatal care. During the cesarean delivery; maternal and cord blood, subcutaneous and omental adipose tissue samples were obtained. The adipose tissues were snap frozen in liquid nitrogen and stored in −80°C freezer. The patient recruitment and study protocol was approved by Cedars-Sinai Medical Center Institutional Review Board. In this report, we focus on the KEGG adipocytokine pathway. Other KEGG pathways that are relevant to insulin resistance and diabetes in pregnancy that we are studying for other reports are complement and coagulation; Cytokine-cytokine receptor interaction, Arachidonic acid metabolism and insulin signaling pathways.

2.2. RNA Extraction and Labeling

Total RNA was extracted from adipose tissues using RNeasy Lipid Tissue kit from Qiagen following the manufacturer’s instructions. Briefly, about 30 mg of frozen adipose tissues were resected and disrupted in 1 ml QIAzolysis reagent with handheld tissue homogenizer (VWR). The homogenates were incubated at room temperature for 5 min followed by mixing with 200 ul chloroform (Sigma Aldrich) and centrifuging at 12,000 g for 15 min at 4°C. The top aqueous phase of the homogenates containing total RNA were then mixed with 600 ul 70% ethanol (Sigma Aldrich) and loaded onto RNeasy Mini spin column to capture the RNA onto the column’s membrane after brief centrifugation at about 10,000 g. On column DNA digestion with RNase-free DNase I set (Qiagen) was carried out to get rid of carry-over genomic DNA. RNA was washed twice and eluted from the membrane with RNase-free water. The concentration and purity of RNA were measured with UV spectrometer (Bio-rad). RNA integrity was checked with Agilent Bio-analyzer with RNA 6000 nano kit.

IlluminaTotalPrep RNA Amplification kit (Ambion) was used to generate biotin-labeled cRNA from total RNA. Briefly, first strand cDNA was made from about 300 ng of total RNA with oligoT7 primer, dNTP, RNase inhibitor, and ArrayScript reverse transcriptase in first strand buffer, incubated at 42°C for 2 hours. Then second strand cDNA was synthesized at 16°C for 2 hours with DNA polymerase, dNTP mix, RNase H, and second strand buffer. After purification of cDNA with cDNA-Pure magnetic beads, in vitro transcription (IVT) was carried out with biotin-labeling NTPs and IVT enzymes to synthesize biotin-labeled cRNA at 37°C for 14 hours. Finally, cRNA was purified using RNA binding magnetic beads and eluted with cRNA elution buffer.

2.3. Microarray Hybridization Staining and Scanning

Biotin labeled cRNA (750 ng) was loaded on to Illumina HumanHT-12 V4.0 Expression BeadChip, which comprises probes targeting more than 47,000 transcripts across whole
genome, in hybridization buffer with hybridization controls and incubated for 16 hours at 58°C. After hybridization, BeadChips were washed, blocked with blocking buffer and stained with streptavidin-Cy3 (Amersham Biosciences). Images of stained BeadChips were captured by IlluminaBeadArray Reader.

2.4. Microarray Image Processing and Data Analysis

Images of BeadChip were loaded into IlluminaGenomeStudio for quality determination by evaluation of the present call percentages, signal intensities of hybridization control, biotin controls, and negative controls. Quantile normalization was applied during data processing in GenomeStudio. Signal intensities of each gene/probe were exported into Partek Genomic Suite 6.5 for high level data analyses. Partek built-in ANOVA model was used to evaluate the impacts of various variables in the study such as different adipose tissues, patient ethnicity, patient-to-patient variability, etc., on the expression data set. Differentially expressed genes (DEGs) of omental fat versus subcutaneous fat were defined as 1.5-fold difference in either direction plus pair-wise t-test with Benjamini & Hochberg adjusted p < 0.05. Functional classification and pathway analysis were carried out using DAVID Bioinformatics Resources 6.7 (National Institute of Allergy and Infectious Diseases, NIAID, NIH) [13,14].

A heat-map is a rectangular tiling of data with cluster trees appended to its margins [15]. Weinstein describes the heat map as follows: in the case of gene expression data, the color assigned to a point in the heat map grid indicates how much of a particular RNA or protein is expressed in a given sample. The gene expression level is generally indicated by red for high expression and either green or blue for low expression. Coherent patterns (patches) of color are generated by hierarchical clustering on both horizontal and vertical axes to bring like together with like. Cluster relationships are indicated by tree-like structures adjacent to the heat map, and the patches of color may indicate functional relationships among genes and samples [16]. In our heat-map (Figure 2), tissue samples are displayed on the x-axis while genes are listed on the y-axis. Higher gene expression levels are indicated by red and lower expression levels are indicated by blue or grey. On the vertical and horizontal margins of the tiling there are hierarchical cluster-trees arranging the rows and columns so that similar rows or columns of gene expression levels are near each other [15].

2.5. Real-Time PCR Validation of Microarray Results

We used quantitative RT-PCR to verify the differential expression level of several genes based on either their biological functions or chromosomal locations. Confirmation of genes not present in the adipocytokine pathway helped to control for stochastic biological sampling error exacerbated by multiple testing [12]. Procedurally, selected differentially expressed mRNAs were validated with real-time PCR. RNA was first reverse-transcribed to cDNA using iScript Reverse Transcription Supermix for RT-qPCR (Bio-rad). About 10 ng cDNA were mixed with gene specific primers (Table 1) and Platinum Sybr Green qPCRSuperMix-UDG (Invitrogen). Real-time PCR was carried out in ABI 7000 Sequence Detector (Applied-Biosystems) for 40 cycles. The expression level of human GAPDH gene was used as an internal control. Fold changes of omental adipose tissue group versus subcutaneous group were calculated using CT method.
3. RESULTS

The study is based on 14 patients with a body mass index (BMI) <30 who had an elective Cesarean section performed between 2008 and 2010. The mean age was 32.1 years (SD = 6.21), the mean BMI was 23.3 (SD = 2.88), the mean gestational age at delivery was 39 + 0/7 weeks (SD = 4.37 days), and the mean birth weight was 3240 grams (SD = 384.7 grams) (Table 2). Regarding the ethnic distribution: 40% were Hispanic, 27% African American, 13% Asian, and 20% were non-Hispanic whites.

Categorical factors including fat, BMI, and race were analyzed using ANOVA to estimate the contribution of each factor to our data set and allow the identification of significant sources of variation (Figure 3). Any factor having a ratio greater than an error of 1 was considered significant. As seen in Figure 3, adipose tissue had almost a five-fold effect with an F ratio of 4.77. BMI had a ratio of 2.02 which highlights the impact of BMI and for this reason; we apriori planned to minimize the effect of obesity by excluding from the study any women with a BMI of 30 that would be classified as obesity. Race had a ratio of 1.8. Although the race factor has a value higher than can be contributed to error, when we compared the interaction of race with adipose tissue on differential gene expression using a mixed model ANOVA (column 4) the effect was only 1.25, which is borderline, and suggests minimal to no interference of race on the differential gene expression of adipose tissue.

Six genes of the KEGG Adipocytokine Signaling Pathway orthography were significantly downregulated in omental adipose relative to subcutaneous adipose tissue, (Table 3). Two genes were also found to be significantly upregulated (Table 3). The gene most downregulated in omental adipose tissue was CD36, by a factor of 2.05839. The significantly downregulated genes were found in four cascades within the Adipocytokine Signaling Pathway. In the pathway with initial signaling by Adiponectin; both Adiponectin and Retinoid x receptor alpha were significantly downregulated. In the cascade initiated by TNF-alpha; Insulin Receptor Substrate 1 (IRS1), was significantly downregulated with no significant differential expression of TNF-alpha noted. In the pathway with initial signaling by Leptin, Protein Tyrosine Phosphatase Non-Receptor Type 11 (PTPN11 also known as SHP2), was also significantly downregulated without significant differential expression of Leptin. Finally, both CD36 (FATCD36) and acyl-CoA Synthetase Long-chain Family Member 1 (ACSL1, seen in Figure 2 as FACS) involved in the cascade of free fatty acid uptake and activation were downregulated in omental versus subcutaneous tissue.

Solute Carrier Family 2, Member 1(SLC2A1) also known as GLUT1 was upregulated with a borderline fold increase of 1.59. GLUT1 is a minor facilitated glucose transporter; however no differential expression of GLUT-4 which is the major glucose transporter was observed. Also upregulated was carnitine palmitoyltransferase 1C (CPT1C); this gene is included in the KEGG pathway as part of the CPT-1 gene complex, which comprises the 3 isoforms of CPT1A; CPT1B and CPT1C. The CPT-1 genes are generally involved in fatty acid oxidation but the specific function of CPT1C isoform is poorly understood.

*J Diabetes Mellitus*. Author manuscript; available in PMC 2015 May 28.
Our heat-map shows significantly expressed genes and their relative expression in both subcutaneous and omental adipose tissue samples. The heat map analysis was able to differentiate omental and subcutaneous tissues via hierarchical clustering. The tissues clump together as per the color bar beneath the horizontal cluster tree, the grouping supports the hypothesis that the adipocytokine pathway is activated in the omental tissue (Figure 2).

Table 4 shows the quantitative RT-PCR results for the 7 positional candidate genes, which confirms the differential expression of all five upregulated genes and the two downregulated genes [19]. For example, for the IRS1 gene, the microarray fold change was −1.77, and the RT-PCR fold change was −1.48. We utilized genes not present in the adipocytokine pathways for external validation.

4. DISCUSSION

The objective of this study was to determine differentially expressed genes in omental when compared to subcutaneous adipose tissue in the KEGG Adipocytokine Signaling Pathway orthography, which may be associated with insulin resistance, inflammation, or adverse pregnancy outcomes.

Figure 1 depicts KEGG Adipocytokine Signaling Pathway and shows the cascades signaled by Adiponectin (ADIPO) and Leptin (LEP), the two major adipocytokines, and TNF-alpha (TNFα), a major inflammatory cytokine. Also depicted is a cascade leading to the uptake and activation of Free Fatty Acids via CD36 (FATCD36) and activation via acyl-CoA synthetase long chain family 1 (FACS).

The KEGG pathway cascade arising from TNF-alpha stimulation results in negative regulation of the IRS1 gene. TNF-alpha is an important inflammatory mediator associated with insulin resistance [20], and increased TNF-alpha has been linked to gestational diabetes [21, 22]. A critical function of the IRS1 is to interact with the Insulin Receptor, enabling the metabolic actions of insulin by signaling the PI3K pathway [23]. Thus, IRS1 is a pivotal gene in insulin sensitivity [24–26]. Of note is that IRS1 gene variations have been associated with increased in visceral to subcutaneous fat ratio as determined by computerized tomography of the abdomen [24]. In our study, IRS1 was downregulated in the omental adipose tissue, suggesting increased insulin resistance in that tissue. Another study showed significantly reduced IRS1 mRNA levels in adipocytes from obese compared to lean non-pregnant Pima Indians. Further, a role for IRS1 in the pathogenesis of type 2 diabetes has been suggested because of differential expression of IRS1 variants [23]. We did a PUBMED search using the following phrases “insulin receptor”, insulin receptor protein”, “adipose tissue”, “omentum”, “pregnancy”, “pregnancy complications”, “diabetes in pregnancy” and we could not find any report on downregulation of IRS1 in omental compared to subcutaneous tissue in non-obese healthy, nondiabetic pregnant women; consequently we believe that this finding is a contribution to the literature.

Protein Tyrosine Phosphatase, Non-Receptor Type 11 (PTPN11 also known as SHP2) was also downregulated in the omental adipose depot. The KEGG orthography notes SHP2 (PTPN11) is involved in signaling the MAPK signaling pathway, with consequences to cell
growth and development. This is through activation by SHP2 of MAPK/ERK in response to leptin [29]. It has also been demonstrated that interactions between SHP2 and IRS1 promotes binding of IRS1 to the insulin receptor. SHP2, then, acts as an adaptor for insulin receptor and IRS1 forming a multiprotein signaling complex involving all three proteins to enhance glucose uptake. Downregulation of expression of SHP2, in the omental adipose depot [30] may serve to further predispose to insulin resistance.

In another signaling cascade, Adiponectin (ADIPO) was found to be downregulated in the omental depot in our study. As shown in the KEGG pathway, Adiponectin signals increased glucose uptake via the GLUT transporters [29,30]. To establish the involvement of adiponectin in insulin resistance in pregnancy, Cortelazzi et al. showed significantly lower adiponectin serum levels in women with GDM than in nondiabetic women at the same gestational ages [16]. Other studies have also shown decreases in serum adiponectin in late normal pregnancy [31,32]. Reports have shown that adiponectin is associated with improved glucose sensitivity, central body fat distribution, and that serum adiponectin concentrations are determined mainly by visceral adipose [33]. Our findings of differential downregulation of adiponectin in omental tissue in healthy non-obese pregnant women adds to this literature and support the association between visceral fat and increased insulin resistance.

Retinoid × Receptor, alpha (RXR) was also downregulated in omental adipose in our study. The KEGG Pathway shows that RXR forms a heterodimer with PPAR-alpha, and that PPAR-alpha is activated via leptin and adiponectin stimulation [34,35]. Activation of PPAR-alpha promotes uptake and utilization of fatty acids by upregulation of genes in fatty acid transport and beta-oxidation [36]. Downregulation of RXR can then lead to diminished fatty acid uptake and utilization in omental adipose tissue. RXR-alpha also forms a heterodimer with Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma), not shown on the KEGG pathway, which binds to promoter sites and directly stimulates transcription of adiponectin. Of note, this is the site of action of thiazolidinedione rosiglitazone, which activates the PPAR-gamma-RXR-alpha heterodimers bound to PPAR-gamma response elements in the adiponectin promoter [43]. PPAR-gamma was also found in our study to be downregulated in omental adipose (−1.632 89 fold change, P = 0.006 071 56), further increasing insulin resistance.

CD36 (FATCD36), found to be downregulated in omental adipose, is involved in the uptake of free fatty acids from the plasma [37,38]. ACSL1 (FAT) also downregulated in omental adipose in our study is responsible for activation of free fatty acids for utilization within the cell. Decreased activity of this enzyme decreases the rate of fatty acid storage. Notably, a study showed that the content/activity of fatty acid storage enzymes in omental fat was dramatically lower in those with more visceral fat [39]. Recent evidence supports the role of CD36 in storing fatty acids in adipose tissue. The actions of these proteins prevent the adverse physiologic effects from high circulating free fatty acid (FFA) levels [39,40]. High circulating FFA levels can also lead to pro-inflammatory processes that impair insulin signaling in liver, adipose, and skeletal muscle leading to insulin resistance [41,42]. It has been shown that CD36 membrane levels and turnover are abnormal in diabetes, resulting in dysfunctional fatty acid utilization. Also, variants in the CD36 gene have been shown to increase susceptibility to the metabolic syndrome increasing risk for diabetes and
cardiovascular disease [40]. Thus, the downregulation of these two genes in omental adipose tissue may predispose to hyperlipidemia and its sequelae.

GLUT 1 was upregulated in omental adipose in our study. It functions as a basal constitutive glucose transporter, however GLUT-1 is minimally, if at all upregulated in the plasma membrane by insulin stimulation in skeletal muscle and adipocytes [44–46]. It has been widely observed that insulin-dependent glucose influx in skeletal muscle and adipocytes relies largely on GLUT-4, not GLUT-1. Moreover, it has been shown that insulin resistance in skeletal muscle and adipose is caused by abnormalities in glucose transport via GLUT-4 [47], which we did not find to be differentially expressed in our study. GLUT-1 was found to be downregulated in skeletal muscle of gestational diabetic women relative to that of normal glucose tolerant pregnant women with no differential expression in subcutaneous adipose tissue. Importantly, GLUT-4 was downregulated in both adipose and skeletal muscle of gestational diabetic women in the same study [48]. Of note, elevation of GLUT-1 expression in adipocytes has been observed in insulin resistant animal models. One study suggests this may be part of a compensatory mechanism for glucose entry in a condition in which normal insulin-stimulated glucose uptake is attenuated [49]. Another report noted that high fat feeding may link GLUT1 upregulation mechanistically via oxidative stress through chronic increased glucose influx to diet-induced insulin resistance [50]. Thus current evidence does not support a role for GLUT1 in insulin sensitivity in adipose tissue.

Carnitine palmitoyl transferase 1C (CPT1C) mRNA was found to be upregulated in omental adipose. The CPT1C isoform is atypical of CPT1 family proteins since it does not seem to be functionally related to CPT1A and CPT1B but seem to appear in the same category because it has high sequence similarity to them [51]. CPT1C has been shown to be primarily expressed in brain tissue; thus its upregulation noted in our study maybe a novel finding [52,53]. Unlike CPT1A and CPT1B, CPT1C is unable to catalyze acyl transfer from fatty acyl-CoAs to carnitine [53]. Recent studies have shown that CPT1c expression is localized in the ER and not in mitochondrial membrane which suggests that it may be less involved with fatty acid oxidation, and may be closer involved with palmitate transport across ER membrane, or perhaps as a metabolic sensor [51]. These findings underscore the poorly understood involvement of this gene in the regulation of energy homeostasis.

Limitations of this study include the utilization of a heterogeneous ethnic group. It is well accepted that risks of insulin resistance and diabetes may differ by ethnicity [54,55]. However our ANOVA analysis showed the minimal contribution of ethnicity to variation of the differently expressed genes. It is also possible that we could have used a larger sample size. However a review of the literature shows similar sample size in comparable studies [56–58]. We attempted to limit the influence of obesity on our study findings by excluding patients who are classified as obese with a BMI of 30; however we noted that some variation of our study may still be due to BMI since the F ratio was approximately 2 in the ANOVA analysis. A next step would be to perform metabolic testing to confirm function of the expressed genes.

It is acknowledged that adipose tissue is metabolically active and that intra-abdominal fat contributes to the pathophysiology of insulin resistance and inflammation [59]. Elucidation
of the mechanisms of metabolic function of adipose tissue is ongoing. Most studies on adipose tissue are in the general population with fewer studies performed on pregnant women. The pathophysiology of adipose tissue function and insulin resistance in pregnancy is still not well understood, and may not necessarily be identical to that in the non-pregnant state. It is well accepted that obesity affects metabolic function, thus in this study we utilized only non-obese pregnant women in order to exclude the effect of obesity and assess the effect of pregnancy. In this study, we have shown the downregulation of several key genes in the KEGG Adipocytokine Pathway in omental when compared to subcutaneous adipose tissue, in which downregulation is linked to insulin resistance or inflammation. We observed borderline upregulation of GLUT-1, and have noted that the literature suggests this not have any significant role in insulin sensitivity in adipose tissue. As discussed, the upregulated gene CPT1C is poorly understood but we saw novel differential expression in omental adipose tissue. We believe that the findings from our study may contribute to literature on the metabolic activity of omental adipose tissue in pregnancy.

REFERENCES

1. Ryan EA, Enns L. Role of gestational hormones in the induction of insulin resistance. Journal of Clinical Endocrinology and Metabolism. 1988; 67:341–347. doi:10.1210/jcem-67-2-341. [PubMed: 3292560]

2. Mastorakos G, Valsamakis G, Papatheodorou DC, Barlas I, Margeli A, Boutsiadis A, Kouskouni E, Vitoratos N, Papadimitriou A. The role of adipocytokines in insulin resistance in normal pregnancy: Visfatin concentrations in early pregnancy predict insulin sensitivity. Clinical Chemistry. 2007; 53:1477–1483. doi:10.1373/clinchem.2006.084731. [PubMed: 17586594]

3. Reece EA, Leguizamon G, Wiznitzer A. Gestational diabetes: The need for a common ground. Lancet. 2009; 373:1789–1797. doi:10.1016/S0140-6736(09)60515-8. [PubMed: 19465234]

4. Kinoshita T, Itoh M. Longitudinal variance of fat mass deposition during pregnancy evaluated by ultrasonography: the ratio of visceral fat to subcutaneous fat in the abdomen. Gynecologic & Obstetric Investigation. 2006; 61:115–118. doi:10.1159/000089456. [PubMed: 16272815]

5. Martin AM, Berger H, Nisenbaum R, Lausman A, MacGarvie S, Crerar C, Ray JG. Abdominal visceral adiposity in the first trimester predicts glucose intolerance in later pregnancy. Diabetes Care. 2009; 32:1308–1310. doi:10.2337/dc09-0290. [PubMed: 19389819]

6. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols. 2009; 4:44–57. doi:10.1038/nprot.2008.211.

7. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Research. 2009; 37:1–13. doi:10.1093/nar/gkn923. [PubMed: 19033363]

8. Hendler I, Blackwell SC, Mehta SH, Whitty JE, Russell E, Sorokin Y, et al. The levels of leptin, adiponectin and resistin in normal weight, overweight and obese pregnant women with and without preeclampsia. American Journal of Obstetrics and Gynecology. 2005; 193:979–983. doi:10.1016/j.ajog.2005.06.041. [PubMed: 16157097]

9. Laivuori H, Kaaja R, Koistinen H, Karonen SL, Andersson S, Koivisto V, et al. Leptin during and after preeclamptic or normal pregnancy: Its relation to serum insulin and insulin sensitivity. Metabolism. 2000; 49:259–263. doi:10.1016/S0026-0495(00)91559-2. [PubMed: 10690955]

10. Vitoratos N, Salamalekis E, Kassanos D, Loghis C, Panayotopoulos N, Kouskouni E, et al. Maternal plasma leptin levels and their relationship to insulin and glucose in gestational-onset diabetes. Gynecologic and Obstetric Investigation. 2001; 51:17–21. doi:10.1159/000052884. [PubMed: 11150869]
11. Kautzky-Willer A, Pacini G, Tura A, Bieglmayer C, Schneider B, Ludvik B, et al. Increased plasma leptin in gestational diabetes. Diabetologia. 2001; 44:164–172. doi:10.1007/s001250051595. [PubMed: 11270672]

12. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. Journal of Biological Chemistry. 2003; 278:9073–9085. doi:10.1074/jbc.M207198200. [PubMed: 12496257]

13. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. Journal of Clinical Investigation. 2006; 116:1784–1792. doi:10.1172/JCI29126. [PubMed: 16823476]

14. Cortelazzi D, Corbetta S, Ronzoni S, et al. Maternal and foetal resistin and adiponectin concentrations in normal and complicated pregnancies. Clinical Endocrinology. 2007; 66:447–453. doi:10.1111/j.1365-2265.2007.02761.x. [PubMed: 17302882]

15. Chen J, Tan B, Karteris E, Zervou S, Digby J, Hillhouse EW, et al. Secretion of adiponectin by human placenta: Differential modulation of adiponectin and its receptors by cytokines. Diabetologia. 2006; 49:1292–1302. doi:10.1007/s00125-006-0194-7. [PubMed: 16570162]

16. Winzer C, Wagner O, Festa A, Schneider B, Roden M, Pacini G, et al. Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care. 2004; 27:1721–1727. doi:10.2337/diacare.27.7.1721. [PubMed: 15202053]

17. Wilkinson L, Friendly M. The history of the cluster heat map. The American Statistician. 2009; 63:179–184. doi:10.1198/tas.2009.0033.

18. Weinstein JA. Postgenomic visual icon. Science. 2008; 319:1772–1773. doi:10.1126/science.1151888.

19. Lee YH, Nair S, Rousseau E, Allison DB, Page GP, Tataranni PA, et al. Microarray profiling of isolated abdominal subcutaneous adipocytes from obese vs non-obese Pima Indians: increased expression of inflammation-related genes. Diabetologia. 2005; 48:1776–1783. doi:10.1007/s00125-005-1867-3. [PubMed: 16059715]

20. Borst SE. The role of TNF-alpha in insulin resistance. Endocrine. 2004; 23:177–182. doi:10.1385/ENDO:23:2-3:177. [PubMed: 15146098]

21. Kuźmicki M, Szamatowicz J, Kretowski A, Kuć P, Kretowski M, Wawrusiewicz N, et al. Evaluation of adiponectin and TNF-alpha genes expression in women with gestational diabetes. Preliminary results. Ginekologia Polska. 2006; 77:930–936. [PubMed: 17373119]

22. Coughlan MT, Oliva K, Georgiou HM, Permezel JM, Rice GE. Glucose-induced release of tumour necrosis factor-alpha from human placental and adipose tissues in gestational diabetes mellitus. Diabetic Medicine. 2001; 18:921–927. doi:10.1046/j.1464-5491.2001.00614.x. [PubMed: 11703438]

23. Kovacs P, Hanson RL, Lee YH, Yang X, Kobes S, Permana PA, et al. The role of insulin receptor substrate-1 gene (IRS1) in type 2 diabetes in Pima Indians. Diabetes. 2003; 52:3005–3009. doi:10.2337/db02-1200. [PubMed: 14633864]

24. Kilpelainen T, Zillikens MC, Stancakova A, Finucane FM, Ried JS, Langenberg C, et al. Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nature Genetics. 2011; 43:753–760. doi:10.1038/ng.866. [PubMed: 21706003]

25. Rung J, Cauchi S, Albrechtsen A, Shen L, Rocheleau G, Cavalcanti-Proenca C, et al. Genetic variation near IRS1 is associated with reduced adiposity and an impaired metabolic profile. Nature Genetics. 2009; 41:1110–1115. doi:10.1038/ng.1156c. [PubMed: 19734900]

26. Colomiere M, Permezel M, Lappas M. Diabetes and obesity during pregnancy alter insulin signalling and glucose transporter expression in maternal skeletal muscle and subcutaneous adipose tissue. Journal of Molecular Endocrinology. 2010; 44:213–223. doi:10.1677/JME-09-0091. [PubMed: 19955252]

27. Sweeney G. Leptin signalling. Cellular Signalling. 2002; 14:655–663. doi:10.1016/S0898-6568(02)00006-2. [PubMed: 12020765]

28. Kharitonenkov A, Schneekenburger J, Chen Z, Knayzev P, Ali S, Zwick E, et al. Adapter function of protein-tyrosine phosphatase 1D in insulin receptor/insulin receptor substrate-1 interaction.
29. Nedvídková J, Smitka K, Kopský V, Hainer V. Adiponectin, an adipocyte-derived protein. Physiological Research. 2005; 54:133–140. [PubMed: 15544426]

30. Díez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. European Journal of Endocrinology. 2003; 148:293–300. doi:10.1530/eje.0.1480293. [PubMed: 12611609]

31. Fuglsang J, Skjaerbaek C, Frystyk J, Flyvbjerg A, Ovesen PA. Longitudinal study of serum adiponectin during normal pregnancy. BJOG: An International Journal of Obstetric and Gynaecology. 2006; 113:110–113. doi:10.1111/j.1471-0528.2005.00792.x.

32. Catalano PM, Hoegh M, Minium J, Huston-Presley L, Bernard S, Kalhan S, et al. Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism. Diabetologia. 2006; 49:1677–1685. doi:10.1007/s00125-006-0264-x. [PubMed: 16752186]

33. Staiger H, Tsritter O, Machann J, Thamer C, Maerker E, et al. Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obesity Research. 2003; 11:368–372. doi:10.1038/oby.2003.48. [PubMed: 12634431]

34. Suzuki A, Okamoto S, Lee S, Saito T, Shiuchi T, Minokoshi Y. Leptin stimulates fatty acid oxidation and peroxisome proliferator-activated receptor alpha gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the alpha2 form of AMP-activated protein kinase. Molecular and Cellular Biology. 2007; 27:4317–4327. doi:10.1128/MCB.02222-06. [PubMed: 17420279]

35. Takashi TK, Toshimasa TY, Naoto NK, Kazuo KH, Kohjiro KU, Kazuyuki KT. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. Journal of Clinical Investigation. 2006; 116:1784–1792. doi:10.1172/JCI29126. [PubMed: 16823476]

36. Sander K, Josiane S, Jeffrey MP, Frank JG, Beatrice D, Walter W. Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. Journal of Clinical Investigation. 1999; 103:1489–1498. doi:10.1172/JCI21623. [PubMed: 10359558]

37. Love-Gregory L, Abumrad NA. CD36 genetics and the metabolic complications of obesity. Current Opinion in Clinical Nutrition & Metabolic Care. 2011; 14:527–534. doi:10.1097/MCO.0b013e32834bbac9. [PubMed: 21912245]

38. McQuaid SE, Hodson L, Neville MJ, Dennis AL, Cheeseman J, Humphreys SM, et al. Down-regulation of adipose tissue fatty acid trafficking in obesity: A driver for ectopic fat deposition? Diabetes. 2011; 60:47–55. doi:10.2337/db10-0867. [PubMed: 20943748]

39. Zappala G, Rechler MM. IGFBP-3, hypoxia and TNF-alpha inhibit adiponectin transcription. Biochemical & Biophysical Research Communications. 2009; 382:785–789. doi:10.1016/j.bbrc.2009.03.112. [PubMed: 19324019]

40. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of Type 2 diabetes. Endocrine Reviews. 2002; 23:201–229. doi:10.1210/er.23.2.201. [PubMed: 11943743]

41. Olson AL, Pessin JE. The role of adipose tissue and lipotoxicity in the pathogenesis of Type 2 diabetes. Current Diabetes Reports. 2010; 10:306–315. doi:10.1007/s11892-010-0122-6. [PubMed: 20556549]

42. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and Type 2 diabetes. Endocrine Reviews. 2002; 23:201–229. doi:10.1210/er.23.2.201. [PubMed: 11943743]

43. Rudich A, Konrad D, Torok D, Ben-Romano R, Huang C, Niu W, et al. Indinavir uncovers different contributions of GLUT4 and GLUT1 towards glucose uptake in muscle and fat cells and tissues. Diabetologia. 2003; 46:649–658. [PubMed: 12712244]
46. Pilch PF, Wilkinson W, Garvey WT, Ciaraldi TP, Hueckstaedt TP, Olefsky JM. Insulin-Responsive human adipocytes express two glucose transporter isoforms and target them to different vesicles. Journal of Clinical Endocrinology & Metabolism. 1993; 77:286–289. doi:10.1210/jc.77.1.286. [PubMed: 8325954]

47. Shepherd PR, Kahn BB. Glucose transporters and insulin action: Implications for insulin resistance and diabetes mellitus. The New England Journal of Medicine. 1999; 341:248–257. [PubMed: 10413738]

48. Colomiere M, Permezel M, Lappas M. Diabetes and obesity during pregnancy alter insulin signalling and glucose transporter expression in maternal skeletal muscle and subcutaneous adipose tissue. Journal of Molecular Endocrinology. 2010; 44:213–223. doi:10.1677/JME-09-0091. [PubMed: 19955252]

49. Bonini JA, Colca JR, Dailey C, White M, Hofmann C. Compensatory alterations for insulin signal transduction and glucose transport in insulin-resistant diabetes. American Journal of Physiology. 1995; 269:E759–E765. [PubMed: 7485492]

50. Talior I, Yarkoni M, Bashan N, Eldar-Finkelman H. Increased glucose uptake promotes oxidative stress and PKC-delta activation in adipocytes of obese, insulin-resistant mice. American Journal of Physiology-Endocrinology & Metabolism. 2003; 285:E295–E302. [PubMed: 12857675]

51. Sierra AY, Gratacos E, Carrasco P, Clotet J, Urena J, Serra D. CPT1c is localized in endoplasmic reticulum of neurons and has carnitine palmitoyltransferase activity. Journal of Biological Chemistry. 2008; 283:6878–6885. doi:10.1074/jbc.M707965200. [PubMed: 18192268]

52. Price N, van der Leij F, Jackson V, Corstorphine C, Thomson R, Sorensen A, et al. A novel brain-expressed protein related to carnitine palmityl-transferase I. Genomics. 2002; 80:433–442. doi:10.1006/geno.2002.6845. [PubMed: 12376098]

53. Wolfgang MJ, Kurama T, Dai Y, Suwa A, Asaumi M, Matsumoto S, et al. The brain-specific carnitine palmitoyltransferase-1c regulates energy homeostasis. Proceedings of the National Academy of Sciences of the United States. 2006; 103:7282–7287. doi:10.1073/pnas.0602205103.

54. Chiu KC, Cohan P, Lee NP, Chuang LM. Insulin sensitivity differs among ethnic groups with a compensatory response in beta-cell function. Diabetes Care. 2000; 23:1353–1358. doi:10.2337/diacare.23.9.1353.

55. Kuzmicki M, Telejko B, Wawrusiewicz-Kuryłonek N, Kalejta K, Lemancewicz A, Zdrodowski M, et al. The expression of transcription factor 7-like 2 (TCF7L2) in fat and placental tissue from women with gestational diabetes. Diabetes Research and Clinical Practice. 2011; 94:E43–E46. doi:10.1016/j.diabres.2011.07.033. [PubMed: 21855162]

56. Harlev A, Wiznitzer A. New insights on glucose pathophysiology in gestational diabetes and insulin resistance. Current Diabetes Reports. 2010; 10:242–247. doi:10.1007/s11892-010-0113-7. [PubMed: 20425589]
Figure 1.
KEGG Adipocytokine Signaling Pathway.
Downregulated genes are those marked with red stars: ADIPO (Adiponectin), SHP2 (Protein Tyrosine Phosphatase, Non-Receptor Type 11—PTPN11), RXR (Retinoid X-Receptor, alpha), IRS1 (Insulin Receptor Substrate 1), FATCD36 (CD36 molecule, thrombospondin receptor), FACS (acyl-CoA synthetase long-chain family member 1—ACSL1); Upregulated genes are marked with blue stars as they appear in the KEGG gene listing: SLC20A1 (shown as GLUT-1) and CPT1C (listed under CPT-1). Legend of KEGG gene symbols and full gene names for differentially expressed genes appears below [6,7].
Legend of differentially expressed genes in KEGG adipocytokine signaling pathway (Figure 1).

| KEGG Gene Symbol | Official Gene Symbol(s) | Gene name(s) |
|------------------|------------------------|--------------|
| FATCD36          | CD36                   | CD36 molecule (thrombospondin receptor) |
| FACS             | ACSL1, ACSL3, ACSL4, ACSL5, ACSL6 | acyl-CoA synthetase long-chain family member 1, 3, 4, 5, and 6 |
| IRS              | IRS1, IRS2, IRS4       | insulin receptor substrate 1, 2, and 4 |
| SHP2             | LOC344593 or LOC442113 or PTPN11 | protein tyrosine phosphatase, non-receptor type 11 |
| KEGG Gene Symbol | Official Gene Symbol(s) | Gene name(s) |
|------------------|------------------------|--------------|
| ADIPO            | ADIPOQ                 | adiponectin, C1Q and collagen domain containing |
| RXR              | RXRA, RXRB, RXRG       | retinoid × receptor alpha, beta, and gamma |
| GLUT1/4          | SLC2A1, SLC2A4         | solute carrier family 2 (facilitated glucose transporter), member 1, solute carrier family 2 (facilitated glucose transporter), member 4 |
| CPT-1            | CPT1A, CPT1C, CPT1B or CHKB | carnitine palmitoyltransferase 1A (liver), carnitine palmitoyltransferase 1C, carnitine palmitoyltransferase 1B (muscle) or choline kinase beta |

Note where gene symbols/names are separated by a comma, this denotes different genes, but where they are separated by the word “or” this denotes they are synonyms.

**Downregulated/upregulated genes in each gene list are underlined.**
Figure 2.
Heat map of differentially expressed genes (DEGs) in Adipocytokine Signaling Pathway. Each column on the horizontal axis represents a tissue sample. (14 subjects) × (2 tissue samples each, omental and subcutaneous) = 28 total tissue samples. Each row on the vertical axis represents one of the 8 DEGs.
Figure 3.
ANOVA model used to evaluate the impacts of the potential confounding variables: fat, race, BMI, fat and race in the differentially expressed genes in the study population. The horizontal column indicates the Mean F Ratio while the various factors analyzed in the multi factor ANOVA are listed horizontally along the x-axis. Any factor that has a Mean F Ratio more than error (1.00) is considered “significant”.

Sources of Variation

| Factors  | Mean F Ratio |
|----------|--------------|
| Fat      | 4.77         |
| Race     | 1.80         |
| BMI      | 2.02         |
| Fat * Race | 1.25    |
| Error    | 1.00         |
Table 1
Primer sequences for PCR validation of microarray results.

| GeneSymbol | REFSEQ_ID | 5' to 3' Reverse primer | 5' to 3' Forward primer |
|------------|-----------|-------------------------|------------------------|
| GAPDH      | NM_002046 | c a g g t g g t c t c t g a c t t | c c a a t t c g t t g t c a t a c c a |
| IL-6       | NM_000600.3 | g a a a g t g g c t a t g c a g t t g a | g g t a a g c c t a c a c t t c a a g a |
| IL-1B      | NM_000576  | g g g c a a g a a g a t a g c a g t g c t | g a g a c c a c a c a g t c c a a a a |
| CLDN1      | NM_021101  | c c t g g a t t g g t g t c t t g t g | c c g t l a c a g a t g a a g c a a t |
| ADIPOQ     | NM_004797  | t g g c t a t g c t a c a g t c t c a | t c t c t g t g c c t c t g g t t c |
| CFB        | NM_001710  | c a g a c t a t a c c a g g c c a t t g | g l t g c t g g c a a g t g g t a g t t |
| IRS1       | NM_005544  | a c a c g a g g a t a a a a a c a t g g | c t a c g g a a g g a c c a a a a g a |
Table 2

Patient characteristics for study group.

| Race      | Age   | Gestational age | Birth weight (grams) | Maternal weight at delivery (kg) | BMI  |
|-----------|-------|-----------------|----------------------|----------------------------------|------|
| Patient 1 | Afr Am| 33              | 40 + 0               | 3213                             | 75.8 | 22.2 |
| Patient 2 | Afr Am| 28              | 39 + 0               | 3950                             | 77.1 | 25.5 |
| Patient 3 | Afr Am| 41              | 39 + 1               | 3210                             | 88.9 | 26.3 |
| Patient 4 | Asian | 30              | 39 + 5               | 2760                             | 59   | 20.7 |
| Patient 5 | Asian | 31              | 38 + 2               | 3230                             | 78.9 | 23   |
| Patient 6 | Caucasian | 20 | 39 + 0               | 3400                             | 75.4 | 20.8 |
| Patient 7 | Caucasian | 38 | 39 + 0               | 3493                             | 89   | 22.3 |
| Patient 8 | Caucasian | 36 | 37 + 2               | 2850                             | 78.4 | 24.9 |
| Patient 9 | Hispanic | 37 | 39 + 0               | 2769                             | 56.7 | 18.7 |
| Patient 10 | Hispanic | 37 | 39 + 0               | 3420                             | 58   | 21   |
| Patient 11 | Hispanic | 26 | 39 + 1               | 3460                             | 82.6 | 21.7 |
| Patient 12 | Hispanic | 38 | 38 + 5               | 2630                             | 77.1 | 23   |
| Patient 13 | Hispanic | 32 | 39 + 0               | 3760                             | 84.8 | 25.8 |
| Patient 14 | Hispanic | 23 | 38 + 5               | 3210                             | 95.3 | 29.7 |
| Mean      |       | 32.1            | 39 + 0               | 384.7                            | 12.3 | 2.88 |

Afr Am = African American; Age in years; Gestational Age in weeks + days; Birth weight in grams; Maternal weight at delivery in kilograms.
Table 3

Differentially expressed genes in omental relative to subcutaneous adipose tissue.

| Gene symbol | Gene name | Fold-change | P-value  | Function |
|-------------|-----------|-------------|----------|----------|
| IRS1 (IRS)  | Insulin Receptor Substrate-1 | −1.771 63   | 0.000 014 6 | Interacts with insulin receptor and enables insulin metabolic actions by signaling PI3K pathway |
| ADIPOQ (ADIPO) | Adiponectin, C1Q and collagen domain containing | −1.667 34 | 0.039 814 | Signals increased glucose uptake via the GLUT transporters, modulates fatty acid catabolism |
| RXRA (RXR)  | Retinoid X Receptor, alpha | −1.614 26   | 0.000 015 | Activation of PPAR-alpha to promote uptake and utilization of fatty acids |
| CD36        | Thrombospondin receptor | −2.058 39   | 0.000 181 | Uptake of free fatty acids (FFA) from plasma |
| ACSL1 (FACS) | Acyl-CoA synthetase long-chain family member 1 | −1.701 68   | 0.003 205 | FFA activation for triacylglycerol synthesis |
| PTPN11 (SHP2) | Protein tyrosine phosphatase, non-receptor type 11 | −1.733 8    | 0.0 000 256 | Has regulatory role in mitogenic activation, metabolic control, transcription regulation, and cell migration |
| SLC20A1 (GLUT1) | Solute carrier family 2(facilitated glucose transporter), member 1 | 1.589 51    | 0.000 079 4 | Plasma membrane glucose transporter, responsible for basal glucose intake in adipose and skeletal muscle |
| CPT1C (CPT-1) | Carnitine palmitoyltransferase 1C | 1.703 3     | 0.000 060 2 | Function not well understood, believed to play a role in regulation of energy homeostasis |
Table 4
Real-time PCR validation of microarray results.

| Gene  | Ref_seq   | Microarray | RT-PCR |
|-------|-----------|------------|--------|
| IL-6  | NM_000600 | 2.19       | 1.23   |
| IL-1B | NM_000576 | 2          | 1.31   |
| CLDN1 | NM_021101 | 18.61      | 13.89  |
| ADIPOQ| NM_004797 | −1.67      | −1.58  |
| CFB   | NM_001710 | 10.62      | 11.6   |
| IRS1  | NM_005544 | −1.77      | −1.48  |
| PLA2G2A| NM_000300 | 4.48       | 3.5    |